Literature DB >> 15538593

Levodopa reverses gait asymmetries related to anhedonia and magical ideation.

Christine Mohr1, Theodor Landis, H Stefan Bracha, Marc Fathi, Peter Brugger.   

Abstract

Animals and men turn preferentially away from the hemisphere with the more active dopamine (DA) system. Consistent with the idea of a right-hemispheric hyperdopaminergia in schizophrenia, a leftsided turning bias was described for unmedicated psychotic patients. We investigated the modulating role of DA and schizophrenia-like thought on whole-body turns in a controlled double-blind study. The number of veers to either side when walking blindfolded straight ahead (20 meter) was assessed in 40 healthy righthanded men (20 men received levodopa, the remaining participants placebo). Side preferences were analyzed in terms of individuals' positive (Magical Ideation, MI) and negative (Physical Anhedonia, PhysAn) schizotypal features. In the placebo group, increasing MI scores were related to increasing left-sided veering and increasing PhysAn scores were related to increasing right-sided veering. In the levodopa group, this relationship between preferred veering side and type of schizotypy was reversed. The finding in the placebo group suggests an association between MI and a relative right-hemispheric hyperdopaminergia. Unexpectedly, levodopa did not enhance this veering bias, but reversed it, suggesting that psychosis-protective mechanisms exist in the healthy positive "schizotypic" brain. Also unexpectedly, levodopa made "anhedonics" veer like "magics" after placebo, suggesting that DA agonists suppress negative schizotypal symptoms.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15538593     DOI: 10.1007/s00406-004-0531-0

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  60 in total

1.  Brain mechanisms of visual encoding and working memory in psychometrically identified schizotypal individuals and after acute administration of haloperidol.

Authors:  Bruno Kopp; Monika Wolff; Claudia Hruska; Friedel M Reischies
Journal:  Psychophysiology       Date:  2002-07       Impact factor: 4.016

Review 2.  Is there a right hemi-hyper-dopaminergic psychosis?

Authors:  H S Bracha
Journal:  Schizophr Res       Date:  1989 Jul-Oct       Impact factor: 4.939

Review 3.  Dopamine in schizophrenia: a review and reconceptualization.

Authors:  K L Davis; R S Kahn; G Ko; M Davidson
Journal:  Am J Psychiatry       Date:  1991-11       Impact factor: 18.112

4.  Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET.

Authors:  Y Sekine; M Iyo; Y Ouchi; T Matsunaga; H Tsukada; H Okada; E Yoshikawa; M Futatsubashi; N Takei; N Mori
Journal:  Am J Psychiatry       Date:  2001-08       Impact factor: 18.112

5.  Amphetamine psychosis and psychotic symptoms.

Authors:  D S Janowsky; C Risch
Journal:  Psychopharmacology (Berl)       Date:  1979-09       Impact factor: 4.530

6.  Psychotic symptoms in non-clinical populations and the continuum of psychosis.

Authors:  Hélène Verdoux; Jim van Os
Journal:  Schizophr Res       Date:  2002-03-01       Impact factor: 4.939

7.  Topography of the auditory P300 in schizotypal personality.

Authors:  C Klein; P Berg; B Rockstroh; B Andresen
Journal:  Biol Psychiatry       Date:  1999-06-15       Impact factor: 13.382

8.  Human locomotion: levodopa keeps you straight.

Authors:  Christine Mohr; Theodor Landis; H Stefan Bracha; Marc Fathi; Peter Brugger
Journal:  Neurosci Lett       Date:  2003-03-20       Impact factor: 3.046

9.  Amphetamine response and relapse risk after depot neuroleptic discontinuation.

Authors:  B Angrist; E Peselow; M Rubinstein; A Wolkin; J Rotrosen
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

10.  Plasma homovanillic acid in schizotypal personality disorder.

Authors:  L J Siever; F Amin; E F Coccaro; D Bernstein; R J Kavoussi; O Kalus; T B Horvath; P Warne; M Davidson; K L Davis
Journal:  Am J Psychiatry       Date:  1991-09       Impact factor: 18.112

View more
  8 in total

1.  Neurobiological changes of schizotypy: evidence from both volume-based morphometric analysis and resting-state functional connectivity.

Authors:  Yi Wang; Chao Yan; Da-zhi Yin; Ming-xia Fan; Eric F C Cheung; Christos Pantelis; Raymond C K Chan
Journal:  Schizophr Bull       Date:  2014-12-22       Impact factor: 9.306

2.  Empathy, schizotypy, and visuospatial transformations.

Authors:  Katharine N Thakkar; Sohee Park
Journal:  Cogn Neuropsychiatry       Date:  2010-04-30       Impact factor: 1.871

3.  Allostatic load in women with and without PTSD symptoms.

Authors:  Dorie A Glover; Margaret Stuber; Russell E Poland
Journal:  Psychiatry       Date:  2006       Impact factor: 2.458

4.  Lateralized semantic priming: modulation by levodopa, semantic distance, and participants' magical beliefs.

Authors:  Christine Mohr; Theodor Landis; Peter Brugger
Journal:  Neuropsychiatr Dis Treat       Date:  2006-03       Impact factor: 2.570

Review 5.  An Overview of the Association between Schizotypy and Dopamine.

Authors:  Christine Mohr; Ulrich Ettinger
Journal:  Front Psychiatry       Date:  2014-12-19       Impact factor: 4.157

6.  The right way to kiss: directionality bias in head-turning during kissing.

Authors:  A K M Rezaul Karim; Michael J Proulx; Alexandra A de Sousa; Chhanda Karmaker; Arifa Rahman; Fahria Karim; Naima Nigar
Journal:  Sci Rep       Date:  2017-07-14       Impact factor: 4.379

7.  Early uneven ear input induces long-lasting differences in left-right motor function.

Authors:  Michelle W Antoine; Xiaoxia Zhu; Marianne Dieterich; Thomas Brandt; Sarath Vijayakumar; Nicholas McKeehan; Joseph C Arezzo; R Suzanne Zukin; David A Borkholder; Sherri M Jones; Robert D Frisina; Jean M Hébert
Journal:  PLoS Biol       Date:  2018-03-13       Impact factor: 8.029

Review 8.  Cognitive mapping deficits in schizophrenia: a critical overview.

Authors:  Anushree Bose; Sri Mahavir Agarwal; Sunil V Kalmady; Ganesan Venkatasubramanian
Journal:  Indian J Psychol Med       Date:  2014-01
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.